Bayer submits cancer drug for market authorisation in Japan

FRANKFURT Fri Dec 21, 2012 2:10am EST

Related Topics

FRANKFURT Dec 21 (Reuters) - Germany's Bayer has submitted its cancer drug regorafenib, used for the treatment of gastrointestinal stromal tumors, for market authorisation in Japan, it said on Friday. (Reporting by Christoph Steitz)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.